Vertex Acquires Crinetics for $10 Billion! Two New Revenue Drivers and FDA Approvals Provide Momentum!

Billion Acquisition: Vertex acquires Crinetics Pharmaceuticals for $10.0 billion to strategically expand its portfolio outside of cystic fibrosis Pipeline Expansion: FDA approval extension for gene therapy Casgevy and the accelerated approval process for Povetacicept strengthen market position Financial Goals in Focus: For the full year 2026, management expects consolidated revenues of up to $13.1 billion The US biotech company Vertex Pharmaceuticals (VRTX) is making significant investments in the post-cystic fibrosis era. For $85.00...